Brazil has gone through several attempts at defining its pharmaceutical serialization and traceability regulation. The newest version of the law requires ANVISA to develop new regulations, which should result in a more attainable architecture. In this webinar, Dirk Rodgers, Regulatory Strategist at Systech International, will review the features of the new law and the recent draft of regulations from ANVISA. He will also give his quarterly overview of regulatory developments around the rest of the world.

1. WEBINAR AND QUARTERLY REGULATORY UPDATE
14 MARCH, 2017
A Closer Look At Brazil’s New
Serialization Regulation

2. This webinar is
intended to be
interactive
Information contained in
this webinar is current as
of March 2017
Reserve your seat for upcoming
webinars at
www.SystechOne.com/Webinars
We value your
feedback!
BEFORE WE GET STARTED…
WEBINAR SERIES

3. DIRK RODGERS
REGULATORY STRATEGIST
FOR SYSTECH INTERNATIONAL
Dirk is widely acknowledged to be one of the global experts on the current and
emerging set of pharmaceutical regulations on serialization and traceability.
He is the founder of RxTrace.com where he writes regularly in exploration of the
intersection between the pharmaceutical supply chain, track and trace technology,
standards, and regulatory compliance.
PRESENTER

4. 4
History of Brazil’s Pharma Serialization Efforts
Brazil Law Number 13,410-2016
The Latest Draft Regulations From ANVISA
1
2
3
Systech Quarterly Regulatory Update

5. History of Brazil’s Pharma
Serialization Efforts

6. BRAZIL RDC-54 (SUSPENDED)
Implementation timelines
• Phase 1 deadline: December 10, 2015 (serialization and tracing data for 3 batches of product)
• Phase 2 deadline: December 10, 2016 (serialization and tracing for all pharmaceuticals)
Key provisions
• Serialization: Unit-level serialization, using a 2D Data Matrix barcode, which includes a 13-digit ANVISA drug registration number,
unique randomized serial number, expiration date and lot number. These combine to form the ANVISA Unique Identifier of Medicines
(IUM). The serial number cannot be repeated between the units of any product manufactured by the registration holder and, in the
case of importers, between products from the same manufacturer.
• Aggregation: Unit-to-case hierarchy required to support supply chain tracing events.
• Supply Chain Tracing: All movements of units of sale and distribution of medicines must be recorded and stored by the participants
of the pharmaceutical supply chain, including reverse logistics. This includes tracing of transportation activities.
• Manufacturer: Shall maintain the database with record of all movements of the IUM in the pharmaceutical supply chain including:
IUM, identification number (CNPJ) of drug recipients, identification number (CNPJ) of transport companies, date/type of drug
transaction, transport packaging (case) identifier.
• Distributor: Provide serialized product transaction data back to the Manufacturer. Maintain a real-time database of all transactions
managed containing: IUM, identification number (CNPJ) of companies selling to or receiving drugs from the distributor, identification
number (CNPJ) of transport companies, date/type of drug transaction, transport packaging (case) identifier.
• Dispenser / Pharmacy: Provide serialized product transaction data back to the Manufacturer and Distributor. Maintain a real-time
database of all transactions managed containing: IUM, identification number (CNPJ) of companies selling to or receiving drugs from
the dispenser, identification number (CNPJ) of transport companies, date/type of drug transaction, transport packaging (case)
identifier.
• Data Archival: One (1) year after the expiration date of the drug product.

7. BRAZIL RDC-54 (SUSPENDED) SUPPLY CHAIN VIEW
CMO/CPO
ANVISA
Manufacturer Wholesaler Dispenser Pharmacist
Product
Serialization
Repository
Product
Serialization
Repository
Product
Serialization
Repository

8. POLL

9. Brazil Law Number 13,410-2016

10. BRAZIL LAW NUMBER 13,410-2016
Implementation Deadlines
• ANVISA Regulations Published: April 29, 2017 (may be extended if necessary)
• 3-Lot Pilot by Selected Participants: April 29, 2018
• ANVISA Pilot Report & Final Regs: December 29, 2018
• All Products Serialized and Traced: December 29, 2021
Key provisions
• Serialization: Required
• Aggregation: Not specified in the law
• Supply Chain Tracing: Central repository, product movement data provided by each owner in the supply chain
• Data Archival: Not specified in the law, may end up in the regulations

11. The Latest Draft Regulations
From ANVISA

12. DRAFT ANVISA REGULATIONS
Key provisions
• Serialization: Unit-level serialization, using a 2D Data Matrix barcode, which includes a GS1 GTIN,
a 13-digit ANVISA drug registration number, unique serial number, expiration date and lot number.
These combine to form the ANVISA Unique Identifier of Medicines (IUM).
• Aggregation: Not specified in the draft regulation
• Supply Chain Tracing: Central, government-run repository. All members of the supply chain must
upload event data within 3 to 7 days.
• Data Archival: All members of the supply chain must hold a copy of their event data for at least one
year after the drug’s expiration date

13. 101010110010
NEW BRAZIL SUPPLY CHAIN VIEW
CMO/CPOANVISA Manufacturer Wholesaler Dispenser Pharmacist
Central
Product
Movement
Repository
101010110010
Product
Movement
Repository
101010110010
Product
Movement
Repository
101010110010
Product
Serialization
& Movement
Repository

14. QUARTERLY
REGULATORY UPDATE
MARCH 2017

15. New official documents have surfaced:
- October 2016: Proposed pharma serialization pilot
- January 2017: Decree authorizing the pilot
Pilot:
- February 1, 2017 to December 31, 2017
- Voluntary participation
- Final report due, February 1, 2018
The October proposal included a mandatory, 100%
serialization requirement that would start on December 31,
2018 but this was not part of the January decree. It is
unclear if that requirement and deadline are in effect.
RUSSIA

16. New post on CFDA website in January appears to mandate
the use of China’s existing 14-digit National Drug Code as a
“kind-of GTIN substitute”:
• WARNING: Interpreting the meaning of documents
released by the CFDA is notoriously hard.
• “Bit Code” is only unique to the drug, not to the package
• Must be encoded in a barcode on each package
CHINA
AliHealth announced that they will no longer “update” or
offer support for the website that provides the old unique
drug package identifiers.

17. EGYPT

18. UNITED
STATES

19. E.U.
https://www.emvo-medicines.eu/

20. POLL

21. © 2017 Systech International. 21
www.SystechOne.com/resources/

22. 22
SYSTECH REGULATORY UPDATE PDFs
www.SystechOne.com/resources/

23. Please submit your questions
Webinar recording and supplemental booklet will be sent to you
within 48 hours
Let us know how we did by completing a short survey
Q&A
RECORDING
& BOOKLET
SURVEY
COMING UP
Join us for our next webinar on April 12, 2017
Register at www.SystechOne.com/WebinarsNEXT
WEBINAR

24. Q&A
DIRK RODGERS
REGULATORY STRATEGIST | SYSTECH
Email dirk.rodgers@systechone.com
Twitter @RxTrace

25. WHY SYSTECH?
25
Serialization, Track & Trace, Authentication & Engagement
Global And Regional Solutions For All Known Regulations
Proactive Updates To Support Regulation Amendments
Adaptable And Reconfigurable For Changing Business Needs
Global Delivery Teams And Certified Partners With Proven Experience
Post Implementation Support And Training 24x7x365
Proven Innovator With Patented Technologies
ONLY ONE TO DELIVER

26. www.SystechOne.com
THANK YOU FOR JOINING US
SOCIAL MEDIA
LinkedIn
Twitter